Showing results (21-30 of 731) with videos related to
Sort By:
Pageof 74
Plos One|January 30, 2010
Double-detargeted oncolytic adenovirus shows replication arrest in liver cells and retains neuroendocrine cell killing abilityJustyna Leja, Berith Nilsson, Di Yu, et al.Frontiers of Hormone Research|August 26, 2015
Other Novel Therapies: Biomarkers, microRNAs and microRNA Inhibitors, DNA Methylation, Epigenetics, Immunotherapy and VirotherapyValeria Giandomenico, Chrissie Thirlwell, Magnus EssandSeminars in Cancer Biology|March 5, 2017
The cancer-immunity cycle as rational design for synthetic cancer drugs: Novel DC vaccines and CAR T-cellsMohanraj Ramachandran, Anna Dimberg, Magnus EssandPlos One|February 2, 2013
Adenovirus serotype 5 vectors with Tat-PTD modified hexon and serotype 35 fiber show greatly enhanced transduction capacity of primary cell culturesDi Yu, Chuan Jin, Mohanraj Ramachandran, et al.Frontiers in Immunology|November 28, 2022
ZC3H11A loss of function enhances NF-κB signaling through defective IκBα protein expressionMahmoud Darweesh, Shady Younis, Zamaneh Hajikhezri, et al.The Journal of Clinical Investigation|May 16, 2018
CD93 promotes β1 integrin activation and fibronectin fibrillogenesis during tumor angiogenesisRoberta Lugano, Kalyani Vemuri, Di Yu, et al.The Prostate|August 12, 2004
Generation of cytotoxic T lymphocytes specific for the prostate and breast tissue antigen TARPBjörn Carlsson, Thomas H Tötterman, Magnus EssandBJU International|September 8, 2005
The immunotherapy of prostate and bladder cancerThomas H Totterman, Angelica Loskog, Magnus EssandVirology|December 29, 2015
HAdV-2-suppressed growth of SV40 T antigen-transformed mouse mammary epithelial cell-induced tumours in SCID miceChengjun Wu, Xiaofang Cao, Di Yu, et al.Molecular Therapy Oncolytics|April 19, 2021
IFN-I-tolerant oncolytic Semliki Forest virus in combination with anti-PD1 enhances T cell response against mouse gliomaMiika Martikainen, Mohanraj Ramachandran, Roberta Lugano, et al.Pageof 74